Recombinant activated factor VII in patients with acute liver failure with UNOS Status 1A: A single tertiary academic centre experience

Vox Sanguinis

Volumn 106, Issue 1, 2014, Pages 75-82

  Pham, H P ^a   Hsu, S X ^a   Parker Jones, S ^a   Samstein, B ^a   Diuguid, D ^a   Schwartz, J ^a  

^a Department of Medicine   (United States)

Author keywords

Acute fulminant hepatic failure; Novoseven; Recombinant activated factor VII; Transfusion

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ACUTE KIDNEY FAILURE; ACUTE LIVER FAILURE; ADULT; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BRAIN EDEMA; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INTRACRANIAL PRESSURE MONITORING; KIDNEY FAILURE; LENGTH OF STAY; LIVER TRANSPLANTATION; MALE; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTHROMBIN TIME; RETROSPECTIVE STUDY; SURVIVAL RATE; THROMBOCYTE; THROMBOEMBOLISM; TREATMENT OUTCOME;

ACUTE FULMINANT HEPATIC FAILURE; NOVOSEVEN; RECOMBINANT ACTIVATED FACTOR VII; TRANSFUSION;

ADULT; BLOOD COMPONENT TRANSFUSION; FACTOR VIIA; FEMALE; HEMORRHAGE; HUMANS; INTENSIVE CARE UNITS; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; OFF-LABEL USE; PROTHROMBIN TIME; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; THROMBOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84890807753     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12067     Document Type: Article

References (37)

1. Sass DA, Shakil AO: Fulminant hepatic failure. Liver Transpl 2005; 11:594-605
2. Lee WM: Recent developments in acute liver failure. Best Pract Res Clin Gastroenterol 2012; 26:3-16
3. Lee WM: Acute liver failure. Semin Respir Crit Care Med 2012; 33:36-45
4. Pereira SP, Langley PG, Williams R: The management of abnormalities of hemostasis in acute liver failure. Semin Liver Dis 1996; 16:403-414
5. Franchini M, Montagnana M, Targher G, et al.: The use of recombinant factor VIIa in liver diseases. Blood Coagul Fibrinolysis 2008; 19:341-348
6. Kessler CM: New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrate. Curr Opin Hematol 2000; 7:408-413
7. Franchini M, Zaffanello M, Veneri D: Recombinant factor VIIa. An update on its clinical use. Thromb Haemost 2005; 93:1027-1035
8. van't Veer VC, Mann KG: The regulation of the factor VII-dependent coagulation pathway: rationale for the effectiveness of recombinant factor VIIa in refractory bleeding disorders. Semin Thromb Hemost 2000; 26:367-372
9. Butenas S, Brummel KE, Bouchard BA, et al.: How factor VIIa works in hemophilia. J Thromb Haemost 2003; 1:1158-1160
10. Butenas S, Brummel KE, Paradis SG, et al.: Influence of factor VIIa and phospholipids on coagulation in "acquired" hemophilia. Arterioscler Thromb Vasc Biol 2003; 23:123-129
11. Monroe DM, Hoffman M, Oliver JA, et al.: Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99:542-547
12. Shibeko AM, Woodle SA, Lee TK, et al.: Unifying the mechanism of recombinant FVIIa action: dose dependence is regulated differently by tissue factor and phospholipids. Blood 2012; 120:891-899
13. Logan AC, Yank V, Stafford RS: Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records. Ann Intern Med 2011; 154:516-522
14. Logan AC, Goodnough LT: Recombinant factor VIIa: an assessment of evidence regarding its efficacy and safety in the off-label setting. Hematology Am Soc Hematol Educ Program 2010; 2010:153-159
15. Levi M, Levy JH, Andersen HF, et al.: Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010; 363:1791-1800
16. Levy JH, Fingerhut A, Brott T, et al.: Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile. Transfusion 2006; 46:919-933
17. Krisl JC, Meadows HE, Greenberg CS, et al.: Clinical usefulness of recombinant activated factor VII in patients with liver failure undergoing invasive procedures. Ann Pharmacother 2011; 45:1433-1438
18. Raschke RA, Curry SC, Rempe S, et al.: Results of a protocol for the management of patients with fulminant liver failure. Crit Care Med 2008; 36:2244-2248
19. Le TV, Rumbak MJ, Liu SS, et al.: Insertion of intracranial pressure monitors in fulminant hepatic failure patients: early experience using recombinant factor VII. Neurosurgery 2010; 66:455-458; discussion 8
20. Shami VM, Caldwell SH, Hespenheide EE, et al.: Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl 2003; 9:138-143
21. Hendriks HG, Meijer K, de Wolf JT, et al.: Effects of recombinant activated factor VII on coagulation measured by thromboelastography in liver transplantation. Blood Coagul Fibrinolysis 2002; 13:309-313
22. Lodge JP, Jonas S, Jones RM, et al.: Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transpl 2005; 11:973-979
23. Planinsic RM, van der Meer J, Testa G, et al.: Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transpl 2005; 11:895-900
24. Flower O, Phillips LE, Cameron P, et al.: Recombinant activated factor VII in liver patients: a retrospective cohort study from Australia and New Zealand. Blood Coagul Fibrinolysis 2010; 21:207-215
25. Pavese P, Bonadona A, Beaubien J, et al.: FVIIa corrects the coagulopathy of fulminant hepatic failure but may be associated with thrombosis: a report of four cases. Can J Anaesth 2005; 52:26-29
26. Lodge JP, Jonas S, Oussoultzoglou E, et al.: Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. Anesthesiology 2005; 102:269-275
27. Shao YF, Yang JM, Chau GY, et al.: Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Am J Surg 2006; 191:245-249
28. Jeffers L, Chalasani N, Balart L, et al.: Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy. Gastroenterology 2002; 123:118-126
29. Lin Y, Stanworth S, Birchall J, et al.: Use of recombinant factor VIIa for the prevention and treatment of bleeding in patients without hemophilia: a systematic review and meta-analysis. CMAJ 2011; 183:E9-E19
30. Bernstein DE, Jeffers L, Erhardtsen E, et al.: Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 1997; 113:1930-1937
31. Anantharaju A, Mehta K, Mindikoglu AL, et al.: Use of activated recombinant human factor VII (rhFVIIa) for colonic polypectomies in patients with cirrhosis and coagulopathy. Dig Dis Sci 2003; 48:1414-1424
32. Sajjad S, Garcia M, Malik A, et al.: Use of recombinant factor VIIa to correct the coagulation status of individuals with advanced liver disease prior to a percutaneous liver biopsy. Dig Dis Sci 2009; 54:1115-1119
33. Farmer DG, Anselmo DM, Ghobrial RM, et al.: Liver transplantation for fulminant hepatic failure: experience with more than 200 patients over a 17-year period. Ann Surg 2003; 237:666-675; discussion 75-6
34. Atillasoy E, Berk PD: Fulminant hepatic failure: pathophysiology, treatment, and survival. Annu Rev Med 1995; 46:181-191
35. Diness V, Bregengaard C, Erhardtsen E, et al.: Recombinant human factor VIIa (rFVIIa) in a rabbit stasis model. Thromb Res 1992; 67:233-241
36. O'Connell KA, Wood JJ, Wise RP, et al.: Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295:293-298
37. Pham HP, Sireci A, Schwartz J: Using plasma or recombinant factor VIIa for placing intracranial pressure monitors in patients with acute fulminant hepatic failure - A decision analysis approach. Am J Clin Path 2012; 138:460